donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
INDP Indaptus Therapeutics
2.470
-0.120-4.63%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Financial Ratios
Efficiency Ratios TTM
ROIC
-5.64% -61.128% -- -31.232% -- -43.036% -- -43.036%
ROE
-2.8% -62.170% -- -31.371% -- -43.257% -- -43.257%
ROA
-21.36% -50.910% -- -28.215% 81.94% -36.414% 81.94% -36.414%
Efficiency Ratios
Profitability Ratios TTM
Financial Health Ratios
Long-Term Debt to Equity Ratio
-- 0.092% -- 0.151% -- 0.203% -- 0.203%
Total Assets to Common Equity
-22.31% 112.010% -- 111.183% -- 113.028% -- 113.028%
Debt to Asset Ratio
-90.85% 0.414% -- 0.443% -- 0.472% -- 0.472%
Current Ratio
165.79% 9.1814 -- 10.0335 920.77% 8.7719 920.77% 8.7719
Quick Ratio
191.66% 9.1094 -- 9.8318 946.69% 8.5039 946.69% 8.5039
GrowthRatios
Growth Ratios
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
CEO: Meckler, Jeffrey A.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...